Changes in concentrations of ATP and other nucleotides in erythrocytes during erythropoietin treatment in haemodialysis patients

1992 ◽  
Vol 20 (2) ◽  
pp. 93S-93S
Author(s):  
COLIN ADAIR ◽  
TERENCE R.J. LAPPIN ◽  
P. MARY COTES
Keyword(s):  
Erythropoietin Treatment

scholarly journals Transient decrease of serum iron after acute erythropoietin treatment contributes to hepcidin inhibition by ERFE in mice

Haematologica ◽  
2018 ◽  
Vol 104 (3) ◽  
pp. e87-e90 ◽  
Author(s):  
Irene Artuso ◽  
Mariateresa Pettinato ◽  
Antonella Nai ◽  
Alessia Pagani ◽  
Ugo Sardo ◽  
...  
Keyword(s):  
Serum Iron ◽  
Transient Decrease ◽  
Erythropoietin Treatment

scholarly journals Irradiation-induced progenitor cell death in the developing brain is resistant to erythropoietin treatment and caspase inhibition

2004 ◽  
Vol 11 (11) ◽  
pp. 1166-1178 ◽  
Author(s):  
H Fukuda ◽  
A Fukuda ◽  
C Zhu ◽  
L Korhonen ◽  
J Swanpalmer ◽  
...  
Keyword(s):  
Cell Death ◽  
Progenitor Cell ◽  
Developing Brain ◽  
Caspase Inhibition ◽  
Erythropoietin Treatment

Effect of Erythropoietin Treatment on Nutritional Status of Continuous Ambulatory Peritoneal Dialysis Patients

1993 ◽  
Vol 13 (2_suppl) ◽  
pp. 544-549 ◽  
Author(s):  
Elias V. Balaskas ◽  
I. Rogers Melamed ◽  
Amit Gupta ◽  
Joanne Bargman ◽  
Dimitrios G. Oreopoulos
Keyword(s):  
Nutritional Status ◽  
Serum Albumin ◽  
Absolute Lymphocyte Count ◽  
Well Being ◽  
Underlying Disease ◽  
Phosphate Binders ◽  
Self Assessment ◽  
Erythropoietin Treatment ◽  
Changes Over Time ◽  
Over Time

Seventeen patients -10 females, 7 males -mean age 52 years (range: 21–77 years), on CAPD for an average of 35 months (range 10–160 months) were studied. Mean initial dose of EPO was 114±45 U/kg/week subcutaneously (range: 59–209). The dose was adjusted to achieve and maintain a target Hb of 100 g/L and Hct 30%. Fifteen of the patients (88.2%) achieved this target within 6 months [baseline to month 6 changes: Hb 72±10 g/L to 107±12 g/L (p=0.0001); Hct 22±3% to 33±4% (p=0.0001)]. Serum total protein also increased significantly over the time of EPO use (p=0.0133); changes from baseline were significant by the fourth month [68±9 g/L to 72±9 g/L (p=0.0115)]. Serum albumin also increased significantly over time (p=0.0157). The change from the baseline result (37±4 g/L) was statistically significant by month 2 (p=0.0060) and was maintained over the following 4 months [month 6 result: 40±3 g/L (p=0.0180)]. The increase was greater for 8 patients with initial serum albumin <35 g/L (mean change 5.75 g/L) than for the 9 subjects with levels >35 g/L (mean change 0.11 g/L). In a comparison group of 17 patients (matched for age, sex, duration of CAPD, underlying disease and antihypertensive treatment), who did not receive EPO treatment, albumin and protein did not appear to increase over time. Mean body weight increased from 60.9± 14.0 kg at the start to 62.1± 13.9 kg at month 6 (p=0.281) and the absolute lymphocyte count from 1.6±0.8 x 109/L to 1.8±1.0 x 109/L (p=0.0472). Serum potassium, urea, creatinine, phosphorus, cholesterol, tri. glycerides, WBC and platelets did not show significant changes over time. Serum phosphorus increased at the end of the second and third months (from 1.6±0.5 mmol/L to 1.9±0.4 and 1.8±0.4 mmol/L and then decreased at the sixth month (1.7±0.5 mmol/L); this is probably due to an increase in phosphate binders in 9 of 17 patients. An improvement in appetite, sleep and well-being, by patients’ self-assessment, was noted during the treatment. We conclude that the treatment with EPO is associated with improvement of the nutritional status of patients on CAPD.

scholarly journals Anemia in the elderly: not always what it seems.

2016 ◽  
Vol 8 ◽  
pp. 2016017
Author(s):  
Marco Cerrano ◽  
Elena Crisà ◽  
Valentina Giai ◽  
Mario Boccadoro ◽  
Dario Ferrero
Keyword(s):  
Positron Emission Tomography ◽  
Elderly Women ◽  
The Elderly ◽  
Steroid Treatment ◽  
Emission Tomography ◽  
Clinical Scenario ◽  
Inflammation Markers ◽  
Positron Emission ◽  
Erythropoietin Treatment ◽  
Anemia Of Chronic Inflammation

Anemia in the elderly is a common but challenging clinical scenario. Here we the described the case of an elderly women who presented with anemia and elevated inflammation markers. After a complete diagnostic workup a clear etiology of the anemia could not be found and eventually a bone marrow biopsy was performed: she was diagnosed with myelodysplastic syndrome. She responded well to erythropoietin treatment but her inflammation markers remained elevated and a positron emission tomography was eventually performed. It turned out that the patient suffered from giant cell artheritis, and after steroid treatment her anemia completely resolved. Our case outlines that it is necessary to pay particular attention to anemia of chronic inflammation, which could be due to several and often masked conditions. Myelodysplatic syndromes should be considered when other causes have been ruled out, but their diagnosis can be difficult and requires expertise in the field. 

Role of Haematocrit in Mediating the Actions of Chronic Erythropoietin Treatment on Blood Pressure and Renal Haemodynamics in the Rat

1993 ◽  
Vol 85 (6) ◽  
pp. 717-724 ◽  
Author(s):  
Chunlong Huang ◽  
Gerard Davis ◽  
Edward J. Johns
Keyword(s):  
Blood Pressure ◽  
Direct Action ◽  
Chronic Administration ◽  
Treated Group ◽  
Recombinant Erythropoietin ◽  
Doppler Flowmetry ◽  
Human Recombinant Erythropoietin ◽  
Vascular Responsiveness ◽  
Erythropoietin Treatment ◽  
Renal Vascular

1. This investigation aimed to study the effect of chronic administration of human recombinant erythropoietin on haematocrit, blood pressure, renal cortical and papillary resistances and vascular responsiveness to vasoconstrictor agents. 2. Rats were treated with placebo or 25, 50 or 100 units/kg erythropoietin subcutaneously, every other day for 3 weeks. Animals were then anaesthetized with sodium pentobarbitone and were prepared for laser-Doppler flowmetry measurement in the renal cortex and papilla. 3. Haematocrit in the placebo-treated group was 48.0 + 0.5% and was raised to 52.5 + 0.7, 55.9 + 0.8 and 62.4 + 1.1% (all P <0.05) by the chronic administration of 25, 50 and 100 units/kg doses of the hormone, respectively. Blood pressure was 107 + 1 mmHg in the placebo-treated group and was elevated to 116 + 2 and 130 + 1 mmHg (both P <0.05), respectively, by the two highest doses of erythropoietin. Cortical and papillary perfusions were reduced at the highest dose of erythropoietin, but calculated resistances were increased by 15 and 40% (P <0.05) at 50 and 100 units/kg doses of the hormone, respectively. 4. Infusion of the vasopressor hormones vasopressin and phenylephrine caused increases in blood pressure and decreases in renal cortical and papillary perfusion, the magnitudes of which were only marginally changed by the highest dose of the erythropoietin. Angiotensin II increased blood pressure and decreased cortical perfusion, and the magnitudes of these responses were unchanged by the chronic treatment with erythropoietin. 5. Acute graded increases in haematocrit resulted in significantly (P <0.05) raised blood pressure above a value of 58%. However, renal cortical and papillary perfusions decreased and resistances were increased significantly (P <0.05) when the haematocrit was raised above 56%. 6. The acute transfusion study demonstrated that elevations in blood pressure and renal vascular resistances occurred at haematocrit values somewhat higher than when it was raised by chronic erythropoietin treatment. Thus this would be consistent with the suggestion that erythropoietin has some direct action on the vasculature beyond that resulting from the raised haematocrit. These data show that a low dose regimen of erythropoietin can modestly increase haematocrit without other cardiovascular changes becoming apparent. The findings add weight to the recent clinical practice of using very low doses of the hormone in the treatment of chronic renal failure.

Kinetics of Erythropoiesis in Dialysis Patients Receiving Recombinant Erythropoietin Treatment

1989 ◽  
Vol 4 (5) ◽  
pp. 350-355 ◽  
Author(s):  
Y. Najean ◽  
A. Moynot ◽  
F. Deschryver ◽  
B. Zins ◽  
C. Naret ◽  
...  
Keyword(s):  
Recombinant Erythropoietin ◽  
Dialysis Patients ◽  
Erythropoietin Treatment ◽  
Kinetics Of
Sign in / Sign up

Export Citation Format

Share Document